This video is part of a series of videos on the DREAMM studies.
The roundtable panelists provide an historical overview of the DREAMM-7 and DREAMM-8 trials in multiple myeloma.
The panel was moderated by Dr. Saad Usmani, chief of myeloma service at Memorial Sloan Kettering Cancer Center, along with panelists Dr. Meletios A. Dimopoulos, professor and chairman of the department of clinical therapeutics at the National and Kapodistrian University of Athens School of Medicine, Dr. Hans Lee, director of myeloma research at the Sarah Cannon Research Institute, and Dr. Ajay Nooka is a clinical member of the Cancer Prevention and Control Research Program at Winship Cancer Institute of Emory University.
DREAMM-7 and DREAMM-8 evaluated belantamab mafodotin in combination regimens for relapsed or refractory multiple myeloma. DREAMM-7 tested belamaf with bortezomib and dexamethasone, while DREAMM-8 tested it with pomalidomide and dexamethasone.
Watch more from this conversation here.
Watch Dr. Mateos discuss the DREAMM-7 trial here.
Listen to Drs. Usmani and Lional discuss the journey of belantamab mafodotin in the DREAMM trials on a SOHO Insider podcast earlier in 2025.
Leave feedback about this